Following on from information provided to NICE by the company in June 2019, the appraisal of Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1082 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 March 2020 | Suspended. Topic is suspended |
| 09 March 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation. Following on from information received from the company NICE has decided to suspend this appraisal from its current work programme as company are no longer intending to submit a Marketing Authorisation Application to the European Medicines Agency for this indication at this time. NICE will continue to monitor development and will update interested parties as and when the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual